Worth reading
59In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
Share transferDisclosing companyROHTO PHARMACEUTICAL CO.,LTD.
Execution Date / Effective Date29 May 2026
Impact on Business Performance
Currently under review
Procedures and assumptions
Conditions Precedent to ExecutionRegistration procedures and other matters related to this share transfer
| Item | Details |
|---|---|
| Transaction name | Share transfer |
| Name of the Subject Company | Thann Oryza Co., Ltd. |
| Impact on Business Performance | Currently under review |
| Execution Date / Effective Date | 29 May 2026 |
| Conditions Precedent to Execution | Registration procedures and other matters related to this share transfer |
Items this document does not state (27)
Counterparty nameBusiness Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The completion of the acquisition of shares was delayed until 29 May 2026 because registration procedures and other matters related to the share transfer took longer than expected.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.